Add this result to my export selection Holoclar for treating limbal stem cell deficiency after eye burns (TA467/2) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 August 2017 Recommendation ID TA467/2 Question NICE recommended that further research should be designed to generate robust evidence of the clinical- Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 February 2014 Recommendation ID TA304/1 Question NICE recommended that research should be carried out to determine the relationship between activity Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304/2) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 February 2014 Recommendation ID TA304/2 Question NICE recommended the collection of data on prosthesis failure or on the prevalence of people living Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 July 2012 Recommendation ID TA261/1 Question Further research on the clinical effectiveness of rivaroxaban compared with low molecular weight heparin Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Mifamurtide for the treatment of osteosarcoma (TA235/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 October 2011 Recommendation ID TA235/1 Question Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 June 2009 Recommendation ID TA171/1 Question The Committee considered that rigorous data collection is needed on the life-extending benefits of lenalidomide Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 July 2017 Recommendation ID TA455/1 Question Trials that evaluate utility values (using generic preference-based measures) in children and young Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556/2) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 January 2019 Recommendation ID TA556/2 Question The health-related quality-of-life evidence of patients with perianal fistulas is also lacking, therefore Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 June 2013 Recommendation ID TA287/1 Question There have been no head-to-head trials of rivaroxaban compared with a low molecular weight heparin for Type: Evidence Uncertainties (Remove filter)
Add this result to my export selection Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275/1) Source: National Institute for Health and Care Excellence - NICE (Remove filter) 01 February 2013 Recommendation ID TA275/1 Question There is a need for additional research on the management of bleeds that occur while people are receiving Type: Evidence Uncertainties (Remove filter)